Multimodal MRI of Conduction Tracts and Anatomy of the Cerebral Gray Matter in Familial Risk of Affective Disorders and Schizophrenia.

The present study analyzed diffusion characteristics of white matter tracts and grey matter anatomy in 48 mentally healthy participants, including first-degree relatives of patients with schizophrenia (N=13) and affective spectrum disorders (N=13). The subgroup with familial risk of schizophrenia displayed abnormalities in the structural connectivity and increased cortical thickness in the superior frontal gyrus. No differences in the analyzed characteristics were revealed in the subgroup with familial risk for affective disorders. The results are discussed within the framework of the concepts of endophenotypes and processes reflecting compensatory and protective mechanisms.

[A history and overview of anhedonia in endogenous mental disorders]. / Évoliutsiia vzgliadov na fenomen angedonii pri éndogennoi psikhicheskoi patologii.

Anhedonia is the inability to experience pleasure. This disorder is heterogeneous across psychiatric disorders and is difficult for measuring and submitting to scientific analysis. Over the last several decades there has been increasing interest in the role that anhedonia plays in various psychopathologies. This article reviews the recent literature on anhedonia and its psychopathological features, which are important for prognosis in affective disorders and schizophrenia. Attempts to dissect various subtypes of anhedonia observed in negative syndrome and depression are reviewed as well.

[A differential approach to the improvement of prevention and correction of neuroleptic side extrapyramidal disorders with pantogam activ in patients with schizophrenia]. / Differentsirovannyi podkhod k usovershenstvovaniyu metodov preduprezhdeniya i korrektsii neirolepticheskikh pobochnykh ekstrapiramidnykh rasstroistv preparatom pantogam aktiv u bol'nykh shizofreniei.

AIM: To assess the efficacy and safety of pantogam active (PA) in prevention and correction of neurological side-effects during the course neuroleptic treatment of acute endogenous psychoses. MATERIAL AND METHODS: Eighty schizophrenic patients (mean age 33 years) with acute psychosis were examined. All patients received 28-day course treatment with typical and atypical neuroleptics. Two equal groups were studied: patients of the first group were treated with trihexyphenidyl (THP) in dose of 0,002-0,012 mg and patients of the second group received in addition PA in dose 0,9 mg/day. Clinical-observation, psychometric scales (PANSS, CGI-S, UKU) were administered at baseline and in 1st,3rd,7th, 14th, 21st, 28st day. RESULTS: PA in the combination with THP improved tolerability to neuroleptic therapy in whole and exerted the better correction effect on neuroleptic extrapyramidal disorders (EPD) compared to THP monotherapy. The number of patients with ERD was reduced by 1.5 times and prevention of EPD was observed 3 times more frequent in the group treated with PA. In the THP group, other adverse effects (AE) were 1,7 times more frequent and the total AE score was 2,5 times greater compared to the PA group (131 vs 50). Correction and preventive effects of the combined treatment on the clinically severe symptoms of EPD (akathisia, muscle dystonia) were more frequent in patients treated with typical neuroleptics. A less amount of THP (by 1,2 times) was used to stop EPD in the PA group. CONCLUSION: PA in the combination with THP has demonstrated the clear neuroprotective effect on the development, frequency and clinical presentations of neurological side-effects. The РА can be recommended as a drug of choice for correction and prevention of neuroleptic side-effects, it promotes their tolerability and improves quality of life during the course treatment.